This transaction increases BioIVT’s portfolio of disease-state plasma, sera and controls, and enhances its ability to support the in vitro diagnostic market
Westbury, NY – Aug. 6, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired Keystone Biologicals, Inc., a supplier of disease-state plasma, sera and controls, located in Hatboro, PA. This acquisition will expand BioIVT’s disease-state portfolio both by volume and product range.